The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?

In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants...

Descripción completa

Detalles Bibliográficos
Autores principales: Roguljić, Hrvoje, Arambašić, Jerko, Ninčević, Vjera, Kuna, Lucija, Šesto, Igor, Tabll, Ashraf, Smolić, Robert, Včev, Aleksandar, Primorac, Dragan, Wu, George Y., Smolić, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284020/
https://www.ncbi.nlm.nih.gov/pubmed/35722697
http://dx.doi.org/10.3325/cmj.2022.63.287
_version_ 1784747462894813184
author Roguljić, Hrvoje
Arambašić, Jerko
Ninčević, Vjera
Kuna, Lucija
Šesto, Igor
Tabll, Ashraf
Smolić, Robert
Včev, Aleksandar
Primorac, Dragan
Wu, George Y.
Smolić, Martina
author_facet Roguljić, Hrvoje
Arambašić, Jerko
Ninčević, Vjera
Kuna, Lucija
Šesto, Igor
Tabll, Ashraf
Smolić, Robert
Včev, Aleksandar
Primorac, Dragan
Wu, George Y.
Smolić, Martina
author_sort Roguljić, Hrvoje
collection PubMed
description In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment.
format Online
Article
Text
id pubmed-9284020
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-92840202022-07-29 The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors? Roguljić, Hrvoje Arambašić, Jerko Ninčević, Vjera Kuna, Lucija Šesto, Igor Tabll, Ashraf Smolić, Robert Včev, Aleksandar Primorac, Dragan Wu, George Y. Smolić, Martina Croat Med J Review In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment. Croatian Medical Schools 2022-06 /pmc/articles/PMC9284020/ /pubmed/35722697 http://dx.doi.org/10.3325/cmj.2022.63.287 Text en Copyright © 2022 by the Croatian Medical Journal. All rights reserved. https://creativecommons.org/licenses/by/2.5/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Roguljić, Hrvoje
Arambašić, Jerko
Ninčević, Vjera
Kuna, Lucija
Šesto, Igor
Tabll, Ashraf
Smolić, Robert
Včev, Aleksandar
Primorac, Dragan
Wu, George Y.
Smolić, Martina
The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title_full The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title_fullStr The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title_full_unstemmed The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title_short The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
title_sort role of direct oral anticoagulants in the era of covid-19: are antiviral therapy and pharmacogenetics limiting factors?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284020/
https://www.ncbi.nlm.nih.gov/pubmed/35722697
http://dx.doi.org/10.3325/cmj.2022.63.287
work_keys_str_mv AT roguljichrvoje theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT arambasicjerko theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT nincevicvjera theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT kunalucija theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT sestoigor theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT tabllashraf theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT smolicrobert theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT vcevaleksandar theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT primoracdragan theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT wugeorgey theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT smolicmartina theroleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT roguljichrvoje roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT arambasicjerko roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT nincevicvjera roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT kunalucija roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT sestoigor roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT tabllashraf roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT smolicrobert roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT vcevaleksandar roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT primoracdragan roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT wugeorgey roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors
AT smolicmartina roleofdirectoralanticoagulantsintheeraofcovid19areantiviraltherapyandpharmacogeneticslimitingfactors

Ejemplares similares